KD-496 is under clinical development by Nanjing KAEDI Biotech and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KD-496’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KD-496 overview

KD-496 is under development for the treatment of solid tumors, gastric cancer and pancreatic cancer. The therapeutic candidate is a fourth generation CAR-T cell therapy comprising T cells which are genetically engineered to express chimeric antigen receptor (CAR) by targeting cells expressing Claudin 18.2 (CLDN18.2) and NKG2DL. It is administered through parenteral route.

Nanjing KAEDI Biotech overview

Nanjing KAEDI Biotech., is a pharmaceutical company that develops new CAR, TCR and antibody drugs for the treatment of malignant tumors. The company is headquartered China.

For a complete picture of KD-496’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.